Cited by 1,636RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryDendrimers and Hyperbranched Polymers

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Open access
Akinc, Akin, Maier, Martin A., Manoharan, Muthiah, Fitzgerald, Kevin, Jayaraman, Muthusamy, Barros, Scott, Ansell, Steven, Du, Xinyao +10 more·2019·Nature Nanotechnology

Integrity signals

Registry

Crossref · 10.1038/s41565-019-0591-y

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lipid nanoparticles are widely used in the delivery of mRNA and other nucleic acid drugs.

    “At present, lipid nanoparticles are also widely used in the delivery of mRNA and other nucleic acid drugs.314”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [314]

  • Onpattro, the first siRNA drug approved in 2019, uses lipid nanoparticles to deliver chemically modified siRNA, achieving cell targeting, uptake, and endosomal escape.

    “Onpattro, the first siRNA drug listed in 2019, uses lipid nanoparticles to deliver chemically modified siRNA, which can achieve cell targeting, uptake and endosomal escape.314”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [314]

  • Ionizable lipid-containing LNPs are known to have significantly higher delivery efficiency in hepatocytes after intravenous injection or in muscle cells after intramuscular injection.

    “which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”

    From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [31]

  • The LNP carrier concept is very similar to the FDA-approved siRNA therapeutic Onpattro, which was designed for hepatocyte targeting after intravenous administration.

    “This carrier concept is very similar to the recently FDA-approved siRNA-based therapeutic Onpattro® (Alnylam® Pharmaceuticals) which was designed for hepatocyte targeting after intravenous administration [15]”

    From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [15]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., Mui, B. L., Semple, S. C., Tam, Y. K., Ciufolini, M., Witzigmann, D., Kulkarni, J. A., van der Meel, R., & Cullis, P. R.
Affiliations
  • Alnylam Pharmaceuticals (United States) (US)
  • Acuitas Therapeutics (Canada) (CA)
  • University of British Columbia (CA)
Corresponding author
Cullis, Pieter R.
Venue
Nature Nanotechnology
Published
2019-12
Volume
14
Issue
12
Pages
1084-1087
ISSN
  • 1748-3387 (ISSN-L)
  • 1748-3395
OpenAlex
W2992823069
Cited by
1,636
References
22
Citations by year
2026: 250 · 2025: 312 · 2024: 308 · 2023: 279 · 2022: 239 · 2021: 169 · 2020: 77 · 2019: 1 · 2012: 1
FWCI
40.19
Type
journal article
Language
en
Open access
Locations
  • Nature Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • TU/e Research Portal (submittedVersion)
  • TU/e Research Portal (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
lipid nanoparticles, siRNA, nucleic acid therapeutics, nanomedicine, drug delivery, regulatory approval, transthyretin amyloidosis, clinical translation
MeSH terms
Drug Development, Animals, Drug Carriers, Humans, Polyneuropathies, Drug Delivery Systems, Drug Approval, RNA, Small Interfering, Nanomedicine, Nanoparticles, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review